Author

A. S. Tijsma

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Kim· 2 shared D.-K. Ryu· 2 shared K.-S. Kwon· 2 shared S.-Y. Lee· 2 shared A. N. Jones· 1 shared A. R. Zapata· 1 shared b. Kang· 1 shared C. A. v. Baalen· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

C. Kim

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants

K. E. Zarn, S. A. Jaramillo, A. R. Zapata, N. E. Stone, A. N. Jones, H. E. Nunnally, E. W. Settles, K. Ng, P. S. Keim, S. Knudsen, P. M. Nuijten, A. S. Tijsma, C. T. French

This study shows that stenoparib inhibits SARS-CoV-2 variants in vitro, with EC50 values ranging from 4.1 to 24.1 M, and combination with remdesivir enhances antiviral effects.

bioRxiv · Nov 3, 2021Microbiology

Therapeutic efficacy of CT-P59 against P.1 variant of SARS-CoV-2

S.-Y. Lee, D.-K. Ryu, b. Kang, H. Noh, J. Kim, J.-M. Seo, C. Kim, C. v. Baalen, A. S. Tijsma, H.-Y. Chung, M.-H. Lee, S.-S. Oh, J.-a. Choi, M. Song, K.-S. Kwon

This study evaluates CT-P59's efficacy against the P.1 SARS-CoV-2 variant through in vitro and in vivo tests, showing reduced in vitro neutralization but therapeutic benefit in mice.

bioRxiv · Jul 8, 2021 · PreprintMicrobiology

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

S.-Y. Lee, D.-K. Ryu, Y. K. Choi, P. Moore, C. A. v. Baalen, r. song, A. S. Tijsma, T. Gwete-Moyo, M. Kim, Y.-I. Kim, C. Kim, J.-I. Kim, K.-S. Kwon

This study evaluates CT-P59's efficacy against SARS-CoV-2 variants, showing reduced in vitro neutralization but effective in vivo therapeutic potential against the B.1.351 variant.

bioRxiv · Apr 27, 2021Microbiology